Abacavir

Not Applicable

01/09/2020 Antiretroviral therapies for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

The Ministry of Health’s Drug Advisory Committee has recommended the following antiretroviral therapies (ARTs):

• Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs): lamivudine 150 mg tablet, tenofovir disoproxil fumarate 300 mg tablet, zidovudine 100 mg capsule;

• Non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz 200 mg and 600 mg tablets, etravirine 200 mg tablet, nevirapine 200 mg and 400 mg tablets, rilpivirine 25 mg tablet;

• Protease inhibitors (PIs): atazanavir 200 mg and 300 mg capsules, darunavir 600 mg and 800 mg tablets, lopinavir 200 mg/ritonavir 50 mg tablet and lopinavir 80 mg/ritonavir 20 mg oral solution, ritonavir 100 mg tablet;

• Integrase strand transfer inhibitors (INSTIs): dolutegravir 50 mg tablet, raltegravir 400 mg and 600 mg tablets; and

• Fixed-dose combinations: abacavir 600 mg/lamivudine 300 mg tablet, abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg tablet, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet

in line with their registered indications for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.

Subsidy status

[R] Raltegravir 400 mg and 600 mg tablets, and emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF) in combination with other antiretroviral agents for the treatment of HIV-1 infection.

[R] All other abovementioned ARTs are recommended for the inclusion on the MOH Standard Drug List (SDL).

[NR] SDL subsidy or MAF assistance do not apply to any other ARTs that are not listed above.

Details of all recommendations are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration